Recursion Pharmaceuticals, Inc. RXRX Pre-Tax Income
Pre-Tax Income at other companies
Other financials
Where this comes from
Reported directly by Recursion Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest.
The official record: Recursion Pharmaceuticals, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about Recursion Pharmaceuticals, Inc.'s pre-tax income.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Recursion Pharmaceuticals, Inc.'s pre-tax income?
- Recursion Pharmaceuticals, Inc. (RXRX) reported pre-tax income of -$122.11M in Q1 2026.
- How has Recursion Pharmaceuticals, Inc.'s pre-tax income changed year-over-year?
- Recursion Pharmaceuticals, Inc.'s pre-tax income increased by 39.7% year-over-year, from -$202.65M to -$122.11M.
- What is the long-term trend for Recursion Pharmaceuticals, Inc.'s pre-tax income?
- Over 4 years (2021 to 2025), Recursion Pharmaceuticals, Inc.'s pre-tax income has grown at a 36.4% compound annual growth rate (CAGR), from -$186.48M to -$644.89M.
- What does pre-tax income mean?
- Total income from all sources — operating income plus non-operating items like interest income, investment gains, and other income — before the provision for income taxes.